MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa. (1st February 2015)

• Record Type: Journal Article
• Authors: Hata, H.; Abe, R.; Suto, A.; Homma, E.; Fujita, Y.; Aoyagi, S.; Shimizu, H.
• Is Part Of: British journal of dermatology. Volume 172:Number 3(2015:Mar.)
• Page Start: 769
• Page End: 773
• Publication Date: 2015-02-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.13302
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Recessive dystrophic epidermolysis bullosa (RDEB) is a severe hereditary mechanobullous disease resulting from mutations in the COL7A1 gene, coding for type VII collagen. Patients with RDEB tend to develop squamous cell carcinomas (SCCs) at sites of chronic ulceration or scarring on the whole body. Distinguishing SCC from benign hyperkeratotic lesions is often difficult, not only clinically but also histologically in patients with RDEB. We investigated several matrix metallopeptidase (MMP) subtypes by comparing the DNA amplification microarray findings between evident SCCs and benign hyperkeratotic lesions in the same patient with RDEB. We report that MMP13 was found to be strongly positive in SCCs but negative in benign hyperkeratotic lesions. We found that there is an evident difference in the transitional area between SCCs and benign hyperkeratotic lesions. We propose that MMP13 may be a useful differentiating marker between SCC and benign hyperkeratotic lesions in RDEB. Abstract : What's already known about this topic? In recessive dystrophic epidermolysis bullosa (RDEB), differentiation between squamous cell carcinoma (SCC) and benign hyperkeratotic scar lesions is often difficult, both clinically and histologically. A diagnostic marker for SCC in such patients is urgently required. What does this study add? We have found that the zinc‐dependent matrix metallopeptidase MMP13 is strongly positive in SCC but negative in benign hyperkeratotic lesions of the same patient with RDEB. We propose MMP13 as a marker for differentiating between hyperkeratotic lesions and SCC in patients with RDEB.